Esketamine is approved in Europe for treating resistant major depressive disorder

OPEN Foundation
December 20, 2019

Mahase, E. (2019). Esketamine is approved in Europe for treating resistant major depressive disorder., 10.1136/bmj.l7069
Link to full text

OPEN Foundation

Share This Post

Clinical Trial into Psilocybin Therapy for Psychological Distress in Palliative Care, PsyPal, Receives Medical Ethical Authorisation, with Conditions

Comparing Psychedelic-Assisted Therapy with Traditional Therapy for Mental Illnesses – Part 2

Harnessing Psychedelics for Neurofeedback: A New Frontier in Executive Function Improvement

Psychedelics vs. Traditional Treatments —How Do They Stack Up for Mental Health Disorders? – Part 1

Dutch Psychedelic Practices Shaped by Culture and Law

Do Psychedelic States merely create comforting delusions?

Lessons on Psychedelic Harm Reduction with PsyCare NL – From the field

The Role of Psychedelics in Palliative Care: Real-World Cases – Dr. Houman Farzin, M.D.

The FDA’s Decision on MDMA-Assisted Psychotherapy: A Call for Pragmatism and Scientific Rigor

get the latest

The OPEN Minded Newsletter keeps you informed about the latest psychedelic research & news, articles, exclusive events, job opportunities, programmes, and free resources!

By clicking SUBSCRIBE, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.

Esketamine is approved in Europe for treating resistant major depressive disorder

OPEN Foundation

Share This Post

get the latest

OPEN

ABOUT

EVENTS

RESOURCES

PROGRAMMES

ACTIONS